GET DAILY SIGNALSAcurx Pharmaceuticals (ACXP): $10 Target Suggests +900% Upside from Current Levels
Key Takeaways
- The central stock price target of $10 is the arithmetic mean of three verified analyst targets ($10, $10, and $11), which average roughly $10.33 and round to $10.
- The latest verified price is approximately $0.99, meaning the stock would need to rise roughly 900% to reach the target — a very large move.
- The current analyst range is narrow, from $10 to $11, after H.C. Wainwright cut its target from $31 to $11 in November 2026.
- The strongest supporting factors are a consensus "Strong Buy" rating, a lead antibiotic candidate with multiple clinical "shots on goal," and a clean balance sheet with roughly $10.7 million in cash.
- The biggest risks are clinical-stage status with no product revenue, ongoing cash burn and potential dilution, and a share price already down roughly 80% over the past year.
- For more detail on the company's Major News, Today's Price Move, Forecast, and Earnings, explore these dedicated pages.
- For broader market ideas, explore Trending AI Robots, which track evolving opportunities across thousands of stocks and ETFs.
Analyst Price Targets and Consensus View
Three current, attributable analyst price targets were reviewed. Alliance Global Partners (James Molloy) holds a Buy with a $10 target, Maxim Group (Jason McCarthy) maintains a Buy at $10, and H.C. Wainwright (Matthew Keller) kept its Buy rating but lowered its target to $11 from $31 following the company's Q3 update. The arithmetic mean is about $10.33, which rounds to the central target of $10, with a range of $10 to $11. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The analyst consensus is a Strong Buy. However, the recent H.C. Wainwright reduction signals growing caution about the timeline and probability of clinical success for ibezapolstat. Analysts cite the PATHFINDER study as "another shot on goal" for the lead candidate, but the sharp target cut underscores how binary and uncertain clinical-stage outcomes remain.
Current Market Position and Path Toward the Target
At a verified price near $0.99, the stock trades close to its 52-week low of $0.95 and far below its 52-week high of $7.54. Reaching the $10 central target would require a gain of roughly 900%, which is a very large move by any standard and would far exceed the stock's recent trading history. Acurx Pharmaceuticals, Inc. (ACXP) generates no meaningful product revenue, reporting an EPS loss of about -$2.67 over the trailing twelve months, so any path toward $10 depends almost entirely on positive clinical data, regulatory progress, and renewed investor confidence in the antibiotic pipeline.
What Could Support a Move Toward the Target
The primary catalyst is the lead candidate ibezapolstat, a Gram-positive-selective antibiotic for C. difficile infection, a disease with high recurrence rates and limited novel treatment options. Favorable data from the PATHFINDER study or another clinical readout could materially re-rate a stock that has already fallen roughly 80% in a year. The company's cash position of about $10.7 million provides a runway to advance development, and the unanimous Buy ratings from the three covering analysts reflect a view that the current valuation understates the pipeline's optionality.
What Could Prevent the Target From Being Reached
As a pre-revenue, clinical-stage company, Acurx Pharmaceuticals, Inc. (ACXP) faces binary risk: a failed or underwhelming trial readout could sharply devalue the shares. Ongoing cash burn is likely to require additional capital raises, which may dilute existing holders and pressure the stock. The micro-cap size (a market capitalization near $5 million) makes the shares vulnerable to sharp volatility and limited institutional support. The recent H.C. Wainwright target reduction from $31 to $11 also highlights diminishing confidence in the near-term timeline, and the gap between a roughly $1 share price and a $10 target reflects substantial execution and financing hurdles.
Technical Levels and Market Structure
The stock is trading near its 52-week low of $0.95, a level that now acts as key support; a decisive break below it could signal further downside. On the upside, the $1.00 psychological level is the nearest resistance, followed by the prior trading range that once extended toward $4 and above before the 80% drawdown. Given the extreme decline, meaningful recovery would require sustained buying and positive catalysts rather than technical repair alone.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though the exact timeframe varies by firm. Investors should monitor upcoming clinical data readouts for ibezapolstat and the PATHFINDER study, quarterly cash burn and any financing announcements, and further analyst target or rating revisions. Regulatory interactions with the U.S. Food and Drug Administration and broader sentiment toward small-cap biotech will also influence the path.
Final Assessment
The $10 central target, derived as the mean of three current analyst targets, sits far above the roughly $0.99 share price and would require an extraordinary gain of about 900%. Support comes from a unanimous Buy consensus and a lead antibiotic candidate with multiple clinical opportunities, while the principal obstacles are the company's pre-revenue status, financing risk, and a recent analyst target cut that underscores fading near-term confidence. The narrow $10-to-$11 analyst range reflects general optimism, but the magnitude of the required move and the binary nature of clinical-stage biotech make the outcome highly uncertain. Investors should watch upcoming data readouts and cash-runway disclosures closely.
Using Tickeron AI Daily Buy/Sell Signals in Practice
In my research on volatile names like this one, I often review Tickeron's AI Daily Buy/Sell Signals to track momentum shifts and sentiment changes. The tool applies AI to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and market conditions. It helps surface potential opportunities more efficiently than manual reviews alone, especially for catalyst-driven micro-caps where timing matters.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ACXP in -2.83% downward trend, declining for three consecutive days on November 11, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ACXP declined for three days, in 349 of 373 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for ACXP entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ACXP's RSI Oscillator exited the oversold zone, 38 of 46 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 73 cases where ACXP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for ACXP just turned positive on November 09, 2026. Looking at past instances where ACXP's MACD turned positive, the stock continued to rise in 28 of 39 cases over the following month. The odds of a continued upward trend are 72%.
ACXP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.559) is normal, around the industry mean (3.498). P/E Ratio (-0.434) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. ACXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement